Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Connecticut residents deserve accurate, unexaggerated information about GLP-1 therapy — the actual clinical data, the honest timelines, and a physician who evaluates your real health profile before prescribing. At RealityPeptides, we start every CT patient with the same foundation: the peer-reviewed trial data, not the marketing copy.
The numbers: semaglutide achieved a 14.9% average body weight reduction over 68 weeks in STEP 1 (NEJM 2021). Tirzepatide achieved 20.9% at 15 mg and 22.5% in the highest-dose group of SURMOUNT-1 (NEJM 2022). These are population averages from rigorously controlled trials — your Connecticut physician will translate them into a personalized, honest projection for your starting profile.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
Ozempic® / Wegovy® — NEJM 2021
STEP 1 trial data for Connecticut patients: 14.9% average body weight reduction at 68 weeks, once-weekly injection, n=1,961 participants. The most prescribed GLP-1 in the world, with an extensive post-market safety record that matches its controlled trial outcomes. Your CT physician will review whether this is the right medication for your profile.
Start Real SemaglutideMounjaro® / Zepbound® — NEJM 2022
SURMOUNT-1 trial data for Connecticut patients: dual GIP/GLP-1 agonist. At 15 mg, average weight reduction was 20.9%; the highest-dose group reached 22.5% at 72 weeks (n=2,539). Currently the highest-documented efficacy available in an FDA-approved GLP-1 medication. Your CT physician will assess whether tirzepatide fits your contraindication profile.
Start Real TirzepatideSaxenda® — SCALE Trial, 56 weeks
SCALE trial data for Connecticut patients: 8% average body weight reduction at 56 weeks, daily injection. Over 10 years of post-market real-world safety data make liraglutide the best-characterized GLP-1 for long-term weight management — a reliable, honest option when the newer agents are not appropriate.
Start Real LiraglutideThree randomized controlled trials published in the New England Journal of Medicine establish the evidence base for FDA-approved GLP-1 medications:
authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in .
The documented trial averages: semaglutide 14.9% at 68 weeks (STEP 1, NEJM 2021), tirzepatide 20.9–22.5% at 72 weeks (SURMOUNT-1, NEJM 2022), and liraglutide approximately 8% at 56 weeks (SCALE trial). These are population averages — about half of Connecticut patients in the trials did better, half did less. Your board-certified physician will give you a personalized, honest projection based on your actual BMI, medical history, and health goals before you start.
Initial measurable weight loss typically occurs within 4–8 weeks for Connecticut patients starting GLP-1 therapy. The 12–18 month mark reflects the full clinical trial duration needed to reach the documented 14–22% outcome benchmarks. There is a normal plateau at months 4–6 that can feel discouraging — your CT physician will prepare you for this with the trial data so you stay the course.
The honest answer for CT patients: yes, significant weight regain is documented after stopping GLP-1 therapy. A 2022 withdrawal study following STEP 1 found participants regained approximately two-thirds of their lost weight within 12 months of stopping. Your CT physician will discuss long-term strategies — including maintenance dosing and structured tapering — based on your real data.
Complete our online health intake, receive an honest physician assessment via secure telehealth — a board-certified physician who reads your actual health profile, not an algorithm — and if appropriate, receive your FDA-approved GLP-1 prescription delivered to any Connecticut address within 2–5 business days. No inflated promises. Documented clinical benchmarks from day one.
Local weight loss and GLP-1 providers serving the Connecticut area, based on Google Business listings.
665 N Colony Rd, Wallingford, CT 06492
(203) 269-8000
4.8/5 ★ (53 reviews)
Visit website →Glastonbury, CT
(860) 430-6317
4.9/5 ★ (18 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
